Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tesaro, Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC
Tesaro, Inc.
Universitaire Ziekenhuizen KU Leuven
Aprea Therapeutics
Deciphera Pharmaceuticals, LLC
Opna Bio LLC
AbbVie
Hoffmann-La Roche
Astex Pharmaceuticals, Inc.
Albert Einstein College of Medicine
Medical College of Wisconsin
Merck Sharp & Dohme LLC
Canadian Cancer Trials Group
City of Hope Medical Center
Eisai Inc.
pharmaand GmbH
Hoffmann-La Roche
Morphotek
M.D. Anderson Cancer Center
University of Virginia
University of Washington
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
University of Washington
GOG Foundation
Duke University
Daiichi Sankyo
EMD Serono
Eli Lilly and Company
Pfizer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
GOG Foundation
GOG Foundation
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Gradalis, Inc.
GOG Foundation